CBIO - NASDAQ

Crescent Biopharma, Inc.

CBIO·NASDAQ

$18.45

+8.5%

HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$508.70M

EPS-14.7800

P/E Ratio-1.25

Earnings Date07/30/2026

cbio

Total Non-Current Liabilities

Last Annual Value

1.21M

3-Year CAGR

5-Year CAGR

-11%

10-Year CAGR

17%

Adjust for Inflation

Crescent Biopharma, Inc. Competitors Analysis of Total Non-Current Liabilities

CBIO · NASDAQ

Company	Total Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Crescent Biopharma, Inc. NASDAQ:CBIO	1.21M	162.5%	5.6%	4.8%
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	22.40M	-9.5%	N/A	N/A
Anixa Biosciences, Inc. NASDAQ:ANIX	163.00K	9.8%	-5.8%	-27.7%
Cardiff Oncology, Inc. NASDAQ:CRDF	102.00K	-58.8%	-47.5%	-39.8%
Greenwich LifeSciences, Inc. NASDAQ:GLSI	0.00	N/A	N/A	N/A
PepGen Inc. NASDAQ:PEPG	13.82M	-6.9%	127.6%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	1.09M	-57.7%	-45.9%	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	286.53M	36.0%	48.6%	50.2%
Sangamo Therapeutics, Inc. NASDAQ:SGMO	31.55M	-3.1%	-32.1%	14.1%
C4 Therapeutics, Inc. NASDAQ:CCCC	69.46M	-7.4%	1.1%	N/A
Heron Therapeutics, Inc. NASDAQ:HRTX	145.45M	-6.3%	-1.5%	11.3%

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.45, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $18.45

Related Guides

Blog Categories

Continue your CBIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.